



I, Karen Lee, hereby certify that I am competent to translate from Chinese to English and that the attached translation is, to the best of my knowledge and belief, a true and accurate translation of the following document from Chinese to English.

Excerpt from Ex. 2019 - Bio-Thera Solutions, Ltd. 2021 Annual Report (Chinese)

A handwritten signature in black ink, appearing to read 'K Lee', written over a horizontal line.

Karen Lee

Sworn to before me this
June 15, 2026

A handwritten signature in black ink, appearing to read 'M E', written over a horizontal line.

Signature, Notary Public

Mikhail E. Lezhnev
Notary Public ID No. 02LE0003393
State of New York Qualified in Kings County
Commission Expires on March 22, 2027

Stamp, Notary Public

LANGUAGE AND TECHNOLOGY SOLUTIONS FOR GLOBAL BUSINESS

1250 BROADWAY, 7TH FLOOR, NEW YORK, NY 10001 | T 212.689.5555 | F 212.689.1059 | WWW.TRANSPERFECT.COM

OFFICES IN 92 CITIES WORLDWIDE

Accord BioPharma, Inc.
Exhibit 1097

Accord v. Janssen

IPR2026-00256, -00257, -00258, -00259

Ex. 1097-001

Company Code: 688177

Company Abbreviation: Bio-Thera

Bio-Thera Solutions, Ltd.
2021 Annual Report



Contents

Section I	Definitions	5
Section II	Company Profile and Key Financial Indicators	9
Section III	Management Discussion and Analysis.....	15
Section IV	Corporate Governance.....	61
Section V	Environment, Social Responsibility, and Other Corporate Governance.....	80
Section VI	Significant Events.....	89
Section VII	Changes in Shares and Shareholder Information.....	120
Section VIII	Preferred Share Information.....	130
Section IX	Information Relating to Corporate Bonds	130
Section X	Financial Report.....	131

Documents available for inspection	Financial report signed and sealed by the Company's legal representative, the person in charge of accounting, and the head of the accounting department.
	Original audit report bearing the seal of the accounting firm and the signatures and seals of the certified public accountants.
	Original copies of all Company documents publicly disclosed during the reporting period and the original versions of all announcements.

III. Shareholders and actual controllers

(I) Total number of shareholders

Total number of ordinary shareholders as of the end of the reporting period (accounts)	10,864
Total number of ordinary shareholders as of the end of the month preceding the disclosure date of the annual report (accounts)	10,673
Total number of preferred shareholders with restored voting rights as of the end of the reporting period (accounts)	0
Total number of preferred shareholders with restored voting rights as of the end of the month preceding the disclosure date of the annual report (accounts)	0
Total number of shareholders holding shares with special voting rights as of the end of the reporting period (accounts)	0
Total number of shareholders holding shares with special voting rights as of the end of the month preceding the disclosure date of the annual report (accounts)	0

Number of depositary receipt holders

☐ Applicable ☒ Not Applicable

(II) Shareholdings of the top ten shareholders and top ten circulating shareholders (or shareholders without selling restrictions) as of the end of the reporting period

Unit: shares

Shareholdings of the top ten shareholders								
Name of shareholder (Full name)	Increase/ decrease during the reporting period	Number of shares held at the end of the period	Percent age (%)	Number of restricted shares held	Number of restricted shares including shares lent through securities lending and refinancing	Pledged, marked, or frozen shares		Nature of shareholder
						Status of shares	Qua ntity	
Guangzhou Qixi Group Co., Ltd.	0	159,990,270	38.64	159,990,270	159,990,270	None	0	Domestic non-state-owned legal person
Therabio International Limited	0	47,177,729	11.39	47,177,729	47,177,729	None	0	Overseas legal person
Guangzhou Qiao Xing Investment Partnership (Limited Partnership)	0	23,173,326	5.60	23,173,326	23,173,326	None	0	Domestic non-state-owned legal person
Zhuhai Jifu Qiheng Pharmaceutical Investment Partnership (Limited Partnership)	-60,000	21,499,471	5.19	2,400,000	2,400,000	None	0	Domestic non-state-owned legal person
Guangzhou CAS Yuechuang Incubator Investment Management Co., Ltd. – Guangzhou CAS Yuechuang No. 3 Venture Capital	0	21,333,332	5.15	21,333,332	21,333,332	None	0	Domestic non-state-owned legal person

Partnership (Limited Partnership)								
Guangzhou Xingyu Investment Partnership (Limited Partnership)	0	21,320,002	5.15	21,320,002	21,320,002	None	0	Domestic non-state-owned legal person
Guangzhou Shengyu Investment Partnership (Limited Partnership)	0	16,000,000	3.86	16,000,000	16,000,000	None	0	Domestic non-state-owned legal person
Ji'an Qingyuan District Yichen Enterprise Management Partnership (Limited Partnership)	0	10,744,802	2.59	1,000,000	1,000,000	None	0	Domestic non-state-owned legal person
Guangzhou Fanwanhu Investment Partnership (Limited Partnership)	0	7,424,586	1.79	7,424,586	7,424,586	None	0	Domestic non-state-owned legal person
SHENGFENG LI	0	6,517,332	1.57	6,517,332	6,517,332	None	0	Overseas natural person
Shareholdings of the top ten shareholders without selling restrictions								
Name of shareholder		Number of unrestricted circulating shares held	Type and quantity of shares					
			Type		Quantity			
Zhuhai Jifu Qiheng Pharmaceutical Investment Partnership (Limited Partnership)		19,099,471	RMB ordinary shares		19,099,471			
Ji'an Qingyuan District Yichen Enterprise Management Partnership (Limited Partnership)		9,744,802	RMB ordinary shares		9,744,802			
Hefei Qixing Equity Investment Partnership (Limited Partnership)		4,729,869	RMB ordinary shares		4,729,869			
Huitianze Investment Co., Ltd.		2,133,426	RMB ordinary shares		2,133,426			
Anhui Huizhifu Venture Capital Co., Ltd.		1,855,947	RMB ordinary shares		1,855,947			
Li Xiaofeng		1,460,772	RMB ordinary shares		1,460,772			
Ma Jun		733,860	RMB ordinary shares		733,860			
Lin Zaizhen		410,068	RMB ordinary shares		410,068			
Shenzhen Qianhai Jiaxiang Investment Consulting Co., Ltd.		375,059	RMB ordinary shares		375,059			
Zhou Yu		353,900	RMB ordinary shares		353,900			
Explanation of repurchase special account among the top ten shareholders	Not applicable							
Explanation of entrusted voting rights, proxy	Not applicable							

voting rights, and waiver of voting rights by the above shareholders	
Explanation of related-party relationships or acting-in-concert relationships among the above shareholders	1.Related-party relationships: (1) Qixi Group is ultimately controlled by the actual controllers Yi Xianzhong, Guan Yuchan, and Yi Liangyu; (2) the general partner and executive partner of Xingyu Investment is Yi Liangyu and is ultimately controlled by Yi Liangyu; (3) the general partner and executive partner of Qiao Xing is Guan Yuchan and is ultimately controlled by Guan Yuchan; (4) Qixi Group holds a 74% limited partnership interest in Yuechuang No. 3, and Yuechuang Incubator, in which Guan Yuchan holds a 55% interest, is the general partner of Yuechuang No. 3; (5) the general partner and executive partner of Shengyu Investment is Yi Xianzhong and is ultimately controlled by Yi Xianzhong; (6) the general partner and executive partner of CAS Zhuochuang is Yuechuang Incubator, in which Guan Yuchan holds a 55% interest, and is ultimately controlled by Guan Yuchan. (7) Therabio International is a company 100% owned by LI SHENGFENG (Li Shengfeng); (8) Fanwanhu is a limited partnership in which LI SHENGFENG (Li Shengfeng) and his children hold 100% of the capital contributions, and LI SHENGFENG (Li Shengfeng) serves as the general partner and executive partner. (9) Jifu Qiheng's general partner and executive partner, Jifu Venture Capital Co., Ltd., directly and indirectly holds 100% of the capital contributions in Hefei Jiqiang Equity Investment Management Partnership (Limited Partnership), the general partner and executive partner of Hefei Qixing; (10) Dong Zhengqing, the controlling shareholder of Huitianze (holding 98.8% of Huitianze's equity), is also the largest shareholder of Jifu Venture Capital Co., Ltd. (holding 28.3195% of its shares); (11) Huitianze is also the largest shareholder of Huizhifu (holding 38.92% of its equity). 2.Persons acting in concert (1) Controlling shareholder Qixi Group and its persons acting in concert:Guangzhou Qiao Xing Investment Partnership (Limited Partnership), Guangzhou CAS Yuechuang No. 3 Venture Capital Partnership (Limited Partnership), Guangzhou Xingyu Investment Partnership (Limited Partnership), Guangzhou Shengyu Investment Partnership (Limited Partnership), and Hengqin CAS Zhuochuang Equity Investment Fund Partnership (Limited Partnership); (2) Therabio International Limited and its persons acting in concert: LI SHENGFENG (Li Shengfeng) and Guangzhou Fanwanhu Investment Partnership (Limited Partnership); (3) Zhuhai Jifu Qiheng Pharmaceutical Investment Partnership (Limited Partnership) and its persons acting in concert: Hefei Qixing Equity Investment Partnership (Limited Partnership), Huitianze Investment Co., Ltd., Anhui Huizhifu Venture Capital Co., Ltd., and Shenzhen Jifu Qisheng Investment Partnership (Limited Partnership).
Explanation of preferred shareholders with restored voting rights and the number of shares held	Not applicable

Number of shares held and selling restrictions applicable to the top ten shareholders holding restricted shares

√ Applicable □ Not Applicable

Unit: shares

Serial No.	Name of shareholder holding restricted shares	Number of restricted shares held	Listing status of restricted shares		Selling restrictions
			Date tradable on the market	Number of newly tradable shares	
1	Guangzhou Qixi Group Co., Ltd.	159,990,270	2023-2-21	0	36 months
2	Therabio International Limited	47,177,729	2023-2-21	0	12 months (prior to the Company achieving profitability, no reduction of pre-IPO shares during the three full fiscal years commencing from the listing date of the Company's shares); the lock-up release date is the earlier of February 21, 2023 or the date the Company achieves profitability.
3	Guangzhou Qiao Xing Investment Partnership (Limited Partnership)	23,173,326	2023-2-21	0	36 months
4	Zhuhai Jifu Qiheng Pharmaceutical Investment Partnership (Limited Partnership)	2,400,000	2022-3-28	19,159,471	The 2,400,000 shares acquired through a capital increase within six months prior to the IPO filing may not be transferred within 36 months from March 26, 2019, and therefore the lock-up release date is March 28, 2022; the remaining 19,159,471 shares were released from lock-up on February 22, 2021.
5	Guangzhou CAS Yuechuang Incubator Investment Management Co., Ltd. – Guangzhou CAS Yuechuang No. 3 Venture Capital Partnership (Limited Partnership)	21,333,332	2023-2-21	0	36 months
6	Guangzhou Xingyu Investment Partnership (Limited Partnership)	21,320,002	2023-2-21	0	36 months
7	Guangzhou Shengyu Investment Partnership (Limited Partnership)	16,000,000	2023-2-21	0	36 months
8	Ji'an Qingyuan District Yichen Enterprise Management Partnership (Limited Partnership)	1,000,000	2022-3-28	9,744,802	The 1,000,000 shares acquired through a capital increase within six months prior to the IPO filing may not be transferred within 36 months from March 26, 2019, and therefore the lock-up release date is March 28, 2022; the remaining 9,744,802 shares were released from lock-up on February 22, 2021.
9	Guangzhou Fanwanhu Investment Partnership (Limited Partnership)	7,424,586	2023-2-21	0	12 months (prior to the Company achieving profitability, no reduction of pre-IPO shares during the three full fiscal years commencing from the listing date of the

					Company's shares); the lock-up release date is the earlier of February 21, 2023 or the date the Company achieves profitability.
10	SHENGFENG LI	6,517,332	2023-2-21	0	12 months (prior to the Company achieving profitability, no reduction of pre-IPO shares during the three full fiscal years commencing from the listing date of the Company's shares); the lock-up release date is the earlier of February 21, 2023 or the date the Company achieves profitability.
Explanation of related-party relationships or acting-in-concert relationships among the above shareholders		See the table above under "Section VII. Changes in Shares and Shareholder Information," "III. Shareholders and Actual Controllers," "(II) Shareholdings of the Top Ten Shareholders and Top Ten Circulating Shareholders (or Shareholders Without Selling Restrictions) as of the End of the Reporting Period."			

Number of the Company's top ten domestic depositary receipt holders as of the end of the reporting period

☐ Applicable ☒ Not Applicable

Number held and selling restrictions applicable to the top ten holders of restricted depositary receipts

☐ Applicable ☒ Not Applicable

(III) Table of the top ten shareholders by voting rights as of the end of the reporting period

☐ Applicable ☒ Not Applicable

(IV) Strategic investors or general legal persons becoming top ten shareholders through placement of new shares/depositary receipts

☐ Applicable ☒ Not Applicable

(V) Strategic placement in the initial public offering

1. Holdings acquired through participation in the strategic placement of the initial public offering by special asset management plans established by senior management personnel and core employees

☐ Applicable ☒ Not Applicable

2. Shareholdings acquired through participation in the strategic placement of the initial public offering by subsidiaries related to the sponsor institution

☒ Applicable ☐ Not Applicable

Unit: shares

Name of shareholder	Relationship with sponsor institution	Number of shares/depositary receipts allotted	Date tradable on the market	Increase/decrease during the reporting period	Number held at the end of the period, including shares/depositary receipts lent through securities lending and refinancing
China CICC Wealth Securities Co., Ltd.	Wholly owned subsidiary of the sponsor institution	1,831,501	2022-02-21	0	1,831,501

IV. Information on the Controlling Shareholder and Actual Controllers

(I) Information on the Controlling Shareholder

1. Legal person

☒ Applicable ☐ Not Applicable